Gyre Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 23.11K shares, a 98.19% decline year-over-year.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 423.63K shares, a 9.43% decline year-over-year.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 67.55K shares, a 70.85% decline year-over-year.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-06-30 was 631.06K shares, a 451.01% increase year-over-year.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 2.40M shares, a 174.06% increase from fiscal 2024.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 874.33K shares, a 7150.42% increase from fiscal 2023.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 12.06K shares.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-03-31 | 23.11K shares 10-Q · filed 2026-05-08 | 1.15M shares derived: sum of 4 quarters · filed 2026-05-08 |
| 2025-12-31 | 423.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | 2.40M shares 10-K · filed 2026-03-13 |
| 2025-09-30 | 67.55K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | 2.44M shares derived: sum of 4 quarters · filed 2025-11-07 |
| 2025-06-30 | 631.06K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 2.60M shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 1.27M shares 10-Q · filed 2025-05-09 | 2.09M shares derived: sum of 4 quarters · filed 2025-05-09 |
| 2024-12-31 | 467.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | 874.33K shares 10-K · filed 2025-03-17 |
| 2024-09-30 | 231.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 203.57K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 114.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -28.18K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 60.30K shares 10-Q · filed 2024-05-13 | |
| 2023-12-31 | -203.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | 12.06K shares 10-K · filed 2024-03-27 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | |
| 2022-12-31 | 0.00 shares 10-K · filed 2024-03-27 | |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 5.00K shares 10-K · filed 2022-03-31 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 44.60K shares 10-K · filed 2022-03-31 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 44.60K shares derived: sum of 4 quarters · filed 2021-03-04 |
| 2020-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 44.60K shares derived: sum of 4 quarters · filed 2021-03-04 |
| 2020-03-31 | 44.60K shares 10-Q · filed 2020-05-11 | 73.03K shares derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | 41.22K shares 10-K · filed 2021-03-04 |
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 46.23K shares derived: sum of 4 quarters · filed 2020-02-20 |
| 2019-06-30 | 28.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | 46.23K shares derived: sum of 4 quarters · filed 2020-02-20 |
| 2019-03-31 | 12.79K shares 10-Q · filed 2019-05-02 | 25.45K shares derived: sum of 4 quarters · filed 2020-02-20 |
| 2018-12-31 | 5.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | 12.72K shares 10-K · filed 2020-02-20 |
| 2018-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | |
| 2018-06-30 | 7.65K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | |
| 2018-03-31 | 59.00 shares 10-Q · filed 2018-05-03 | |
| 2016-03-31 | 0.00 shares 10-Q · filed 2016-05-05 | |
| 2015-12-31 | 254.00 shares 10-K · filed 2017-03-08 | |
| 2014-12-31 | 5.73K shares 10-K · filed 2016-03-09 | |
| 2014-06-30 | 9.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | 156.72K shares derived: sum of 4 quarters · filed 2014-08-07 |
| 2014-03-31 | 66.41K shares 10-Q · filed 2014-05-08 | 167.91K shares derived: sum of 4 quarters · filed 2014-08-07 |
| 2013-12-31 | 59.77K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2014-08-07 | 103.10K shares 10-Q · filed 2014-08-07 |
| 2013-09-30 | 21.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-06 | 52.13K shares derived: sum of 4 quarters · filed 2013-11-06 |
| 2013-06-30 | 20.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | 208.38K shares derived: sum of 4 quarters · filed 2013-11-06 |
| 2013-03-31 | 1.59K shares 10-Q · filed 2013-05-08 | |
| 2012-12-31 | 8.80K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2013-11-06 | 231.68K shares 10-Q · filed 2013-11-06 |
| 2012-09-30 | 177.65K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | |
| 2011-12-31 | 305.39K shares 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |